Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338767 · ClinicalTrials.gov registry record · Phase 2
Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy
A Phase 2 study of Depression and HIV Infections, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00338767: Completed Phase 2 study of Depression and HIV Infections, sponsored by Massachusetts General Hospital.
NCT00338767 is a Phase 2 study of Depression and HIV Infections that has completed, run by Massachusetts General Hospital. The registered enrollment target is 150 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00338767, a Phase 2 study of Depression and HIV Infections, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of directly observed therapy plus antidepressant medication in improving adherence to antiretroviral drug therapy among HIV-infected homeless and marginally housed people with depression.
Conditions Studied
Interventions
- DRUG Fluoxetine
- BEHAVIORAL Directly Observed Therapy (DOT)
Study Locations (1)
California
- UCSF Market Street Study Site - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2001-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338767
The ClinicalTrials.gov registry entry for NCT00338767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (81% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Fluoxetine is the first listed.
NCT00338767 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00338767 about?
NCT00338767 is a clinical study titled "Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy". This study will evaluate the effectiveness of directly observed therapy plus antidepressant medication in improving adherence to antiretroviral drug therapy among HIV-infected homeless and marginally housed people with depression.
What is the current status of trial NCT00338767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2001-01. Estimated completion is 2006-08.
What conditions does trial NCT00338767 study?
This clinical trial studies the following conditions: Depression, HIV Infections.
What interventions are being tested in trial NCT00338767?
The interventions under investigation include: Fluoxetine (DRUG), Directly Observed Therapy (DOT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00338767?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00338767 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.